Revvity
Tracked across 2 events · 12 articles · First seen Jun 26, 2026 · Last active Sep 20, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Revvity, Inc. (NYSE: RVTY) announced on September 9, 2026 that it has entered into a definitive agreement to acquire Human Cell Design (HCD), a France-based biotechnology company specializing in human cell models and preclinical research…
Impact: Revvity is the acquirer, expanding its Life Sciences portfolio with HCD's human pancreatic beta cell models and preclinical research capabilities. The deal is expected to close in Q4 2026 subject to regulatory approvals, and its stock reportedly fell 2.3% since the announcement.
Sep 09, 2026 · 6 articles
Tech
Impact: Revvity is listed among the top companies in the epigenetics market, indicating its participation in the industry.
Jun 26, 2026 · 6 articles
90
Revvity entered definitive agreement Human Cell DesignRevvity Acquires Human Cell Design
ERGEN INTELLIGENCE
Track Revvity live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard